Risk of bleeding with dabigatran in atrial fibrillation.

ABSTRACT:

Importance

It remains unclear whether dabigatran etexilate mesylate is associated with higher risk of bleeding than warfarin sodium in real-world clinical practice.

Objective

To compare the risk of bleeding associated with dabigatran and warfarin using Medicare data.

Design, setting, and participants

In this retrospective cohort study, we used pharmacy and medical claims in 2010 to 2011 from a 5% random sample of Medicare beneficiaries. We identified participants as those newly diagnosed as having atrial fibrillation from October 1, 2010, through October 31, 2011, and who initiated dabigatran or warfarin treatment within 60 days of initial diagnosis. We followed up patients until discontinued use or switch of anticoagulants, death, or December 31, 2011.

Exposures</

SUBMITTER: Hernandez I 

PROVIDER: S-EPMC6608584 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature